The late-domain-containing protein p6 is the predominant phosphoprotein of human immunodeficiency virus type 1 particles.
The Gag-derived protein p6 of human immunodeficiency virus type 1 (HIV-1) plays a crucial role in the release of virions from the membranes of infected cells. It is presumed that p6 and functionally related proteins from other viruses act as adapters, recruiting cellular factors to the budding site. This interaction is mediated by so-called late domains within the viral proteins. Previous studies had suggested that virus release from the plasma membrane shares elements with the cellular endocytosis machinery. Since protein phosphorylation is known to be a regulatory mechanism in these processes, we have investigated the phosphorylation of HIV-1 structural proteins. Here we show that p6 is the major phosphoprotein of HIV-1 particles. After metabolic labeling of infected cells with [ortho-32P]phosphate, we found that phosphorylated p6 from infected cells and from virus particles consisted of several forms, suggesting differential phosphorylation at multiple sites. Apparently, phosphorylation occurred shortly before or after the release of p6 from Gag and involved only a minor fraction of the total virion-associated p6 molecules. Phosphoamino acid analysis indicated phosphorylation at Ser and Thr, as well as a trace of Tyr phosphorylation, supporting the conclusion that multiple phosphorylation events do occur. In vitro experiments using purified virus revealed that endogenous or exogenously added p6 was efficiently phosphorylated by virion-associated cellular kinase(s). Inhibition experiments suggested that a cyclin-dependent kinase or a related kinase, most likely ERK2, was involved in p6 phosphorylation by virion-associated enzymes.
Müller
Barbara
B
Abteilung Virologie, Universitätsklinikum Heidelberg, D-69120 Heidelberg, Germany. Barbara.Mueller@med.uni-heidelberg.de
Patschinsky
Tilo
T
Kräusslich
Hans-Georg
HG
D002460:Cell Line; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors; D010450:Endopeptidases / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015683:Gene Products, gag / Q000378:metabolism*; D019833:Genistein / Q000494:pharmacology; D015497:HIV-1 / Q000302:isolation & purification / Q000378:metabolism*; D006801:Humans; D007701:Kinetin; D019950:Mitogen-Activated Protein Kinase 1 / Q000037:antagonists & inhibitors; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors; D010750:Phosphoproteins / Q000378:metabolism*; D010766:Phosphorylation; D011499:Protein Processing, Post-Translational; D017434:Protein Structure, Tertiary; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011687:Purines / Q000494:pharmacology; D012694:Serine / Q000378:metabolism; D013912:Threonine / Q000378:metabolism; D014443:Tyrosine / Q000378:metabolism; D014771:Virion; D054301:gag Gene Products, Human Immunodeficiency Virus
D004791:Enzyme Inhibitors; D015683:Gene Products, gag; D010750:Phosphoproteins; D011687:Purines; D054301:gag Gene Products, Human Immunodeficiency Virus; C083002:p6 gag protein, Human immunodeficiency virus 1; D013912:Threonine; D014443:Tyrosine; D012694:Serine; C090046:olomoucine; D019833:Genistein; D011505:Protein-Tyrosine Kinases; D018844:Cyclin-Dependent Kinases; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases; D010450:Endopeptidases; D007701:Kinetin